CABA Arquivamentos da SEC - Cabaletta Bio, Inc.- Relatório Anual, Declaração de Procuração, Prospecto

Estatísticas Básicas

CIK

1759138

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Cabaletta Bio, Inc.

SEC Filings (Chronological Order)

Esta página fornece uma lista completa e cronológica de Arquivamentos da SEC, excluindo os arquivamentos de propriedade que fornecemos em outro lugar.

June 3, 2026	8-K	FORM 8-K Item 7.01 Regulation FD Disclosure. Item 8.01 Other Events. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 03, 2026 CABALETTA BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39103 82-1685768 (State or Other Jurisdiction of Incorporation) (Commission File
June 3, 2026	EX-99.2	Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document distr Corporate Presentation June 2026 Exhibit 99.2 Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document distributed at or in connection with the presentation (collectively, the “Presentation”) has been prepared by
June 3, 2026	EX-99.1	Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress 83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have Exhibit 99.1 Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress 83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint; all these patients maintained their response off immunomodulators through latest follow-up, as
June 1, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule
May 14, 2026	8-K	FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2026 CABALETTA BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39103 82-1685768 (State or Other Jurisdiction of Incorporation) (Commission File N
May 14, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39103 CABALETTA BIO, INC.
May 14, 2026	EX-99.1	Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting A single infusion of the lowest dose of rese-cel administered without preconditioning, after discontinu Exhibit 99.1 Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting A single infusion of the lowest dose of rese-cel administered without preconditioning, after discontinuation of all immunomodulators, demonstrated compelling drug-free responses for 6 months in 2 of 4 refractory patients; next dose cohort a
May 14, 2026	8-K	FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2026 CABALETTA BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39103 82-1685768 (State or Other Jurisdiction of Incorporation) (Commission File N
May 14, 2026	EX-99.1	Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV® study presented today at ASGCT 20 Exhibit 99.1 Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV® study presented today at ASGCT 2026 Annual Meeting along with initial rese-cel translational data using Cellares’ industrialized, automated manufacturing PC-free rese-cel
May 14, 2026	EX-99.2	Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document distr Corporate Presentation May 2026 Exhibit 99.2 Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document distributed at or in connection with the presentation (collectively, the “Presentation”) has been prepared by
May 4, 2026	EX-1.1	CABALETTA BIO, INC. 51,725,000 Shares of Common Stock UNDERWRITING AGREEMENT EX-1.1 Exhibit 1.1 CABALETTA BIO, INC. 51,725,000 Shares of Common Stock UNDERWRITING AGREEMENT May 4, 2026 TD SECURITIES (USA) LLC GUGGENHEIM SECURITIES, LLC CANTOR FITZGERALD & CO. As Representatives of the several Underwriters c/o TD Securities (USA) LLC 1 Vanderbilt Avenue New York, NY 10017 c/o Guggenheim Securities, LLC 330 Madison Avenue, 8th Floor New York, NY 10017 c/o Cantor Fitzgerald
May 4, 2026	EX-99.2	Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document distr EX-99.2 Corporate Presentation May 2026 Exhibit 99.2 Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document distributed at or in connection with the presentation (collectively, the “Presentation”) has been prep
May 4, 2026	EX-99.1	Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering EX-99.1 Exhibit 99.1 Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering PHILADELPHIA, May 4, 2026 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced today the pricing
May 4, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2026 CABALETTA BIO, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2026 CABALETTA BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39103 82-1685768 (State or Other Jurisdiction of Incorporation) (Commission File Nu
May 4, 2026	424B5	51,725,000 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Nos. 333-278126 PROSPECTUS SUPPLEMENT (To prospectus dated March 31, 2025) 51,725,000 Shares of Common Stock We are selling 51,725,000 shares of our common stock, par value $0.00001 per share, or the common stock, in this offering pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is listed
May 4, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2026 CABALETTA BIO, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2026 CABALETTA BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39103 82-1685768 (State or Other Jurisdiction of Incorporation) (Commission File Nu
April 28, 2026	ARS	ARS CABALETTABIO,INC. 2025ANNUALREPORTUNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM10-K (MarkOne) ☒ ANNUALREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934 ForthefiscalyearendedDecember31,2025 OR ☐ TRANSITIONREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF 1934FORTHETRANSITIONPERIODFROM TO CommissionFileNumber001-39103 CABALETTABIO,INC. (ExactnameofR
April 28, 2026	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted
April 28, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule
April 20, 2026	EX-99.1	Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document distr Corporate Presentation April 2026 Exhibit 99.1 Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document distributed at or in connection with the presentation (collectively, the “Presentation”) has been prepared b
April 20, 2026	8-K	FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2026 CABALETTA BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39103 82-1685768 (State or Other Jurisdiction of Incorporation) (Commission File
April 17, 2026	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted
March 23, 2026	S-8	As filed with the Securities and Exchange Commission on March 23, 2026 As filed with the Securities and Exchange Commission on March 23, 2026 Registration No.
March 23, 2026	EX-21.1	Cabaletta Bio, Inc. Exhibit 21.1 Cabaletta Bio, Inc. The following is a list of subsidiaries of Cabaletta Bio, Inc. as of December 31, 2025. SUBSIDIARY STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION Cabaletta Bio, Inc. Delaware Cabaletta Bio GmbH Switzerland Cabaletta Bio (Germany) GmbH Germany
March 23, 2026	EX-10.8	CABALETTA BIO, INC. 2025 INDUCEMENT PLAN Exhibit 10.8 CABALETTA BIO, INC. 2025 INDUCEMENT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Cabaletta Bio, Inc. 2025 Inducement Plan (the “Plan”). The purpose of the Plan is to enable Cabaletta Bio, Inc. (the “Company”) to grant equity awards to induce highly qualified prospective officers and employees who are not currently employed by the Company and its
March 23, 2026	EX-4.2	Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended Exhibit 4.2 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended The following summary of the general terms and provisions of the registered capital stock of Cabaletta Bio, Inc. (“Cabaletta”, “we”, “our”) does not purport to be complete and is subject to, and qualified in its entirety by, reference to our Third Amended and
March 23, 2026	EX-99.1	Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Rese-cel myositis BLA submission on track for 2027 based on a 17-patient, single arm registrational cohort design, including an outpatient dosing o Exhibit 99.1 Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Rese-cel myositis BLA submission on track for 2027 based on a 17-patient, single arm registrational cohort design, including an outpatient dosing option No-preconditioning program enrolling in lupus and PV; anticipating initial RESET-SLE™ data in 1H26 and durability data from the RES
March 23, 2026	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39103 CABALETTA BIO,
March 23, 2026	EX-99.2	Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document distr Corporate Presentation March 2026 Exhibit 99.2 Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document distributed at or in connection with the presentation (collectively, the “Presentation”) has been prepared b
March 23, 2026	EX-FILING FEES	Calculation of Filing Fee Table Form S-8 (Form Type) Cabaletta Bio, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Cabaletta Bio, Inc.
March 23, 2026	8-K	FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 7.01 Regulation FD Disclosure. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2026 CABALETTA BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39103 82-1685768 (State or Other Jurisdiction of Incorporation) (Commission File
March 23, 2026	EX-10.38	Cabaletta Bio Cellares Corporation Cabaletta Bio, Inc. Exhibit 10.38 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Cabaletta Bio DEVELOPMENT AND CLINICAL MANUFACTURING SERVICES AGREEMENT This Development and Manufacturing Servi
January 12, 2026	8-K	FORM 8-K Item 7.01 Regulation FD Disclosure. Item 8.01 Other Events. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026 CABALETTA BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39103 82-1685768 (State or Other Jurisdiction of Incorporation) (Commission Fi
January 12, 2026	EX-99.1	Cabaletta Bio Announces 2026 Strategic Priorities Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single weight-based dose IND amendment Exhibit 99.1 Cabaletta Bio Announces 2026 Strategic Priorities Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single weight-based dose IND amendment cleared to manufacture rese-cel with the automated, scalable Cellares platform based on multiple successful engineering runs; clinical ma
January 12, 2026	EX-99.2	Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document distr Corporate Presentation January 2026 Exhibit 99.2 Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document distributed at or in connection with the presentation (collectively, the “Presentation”) has been prepared
November 10, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39103 CABALETTA BIO, INC.
November 10, 2025	8-K	FORM 8-K Item 2.02 Results of Operations and Financial Condition. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2025 CABALETTA BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39103 82-1685768 (State or Other Jurisdiction of Incorporation) (Commission F
November 10, 2025	EX-99.1	Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for aut Exhibit 99.1 Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient use All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who would have
October 29, 2025	EX-99.1	Corporate Presentation October 2025 Corporate Presentation October 2025 Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document distributed at or in connection with the presentation (collectively, the “Presentation”) has been prepared by Cabaletta Bio, Inc.
October 29, 2025	8-K	FORM 8-K Item 8.01 Other Events. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2025 CABALETTA BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39103 82-1685768 (State or Other Jurisdiction of Incorporation) (Commission Fi
October 27, 2025	8-K	FORM 8-K Item 7.01 Regulation FD Disclosure. Item 8.01 Other Events. Forward-Looking Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2025 CABALETTA BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39103 82-1685768 (State or Other Jurisdiction of Incorporation) (Commission Fi
October 9, 2025	EX-99.1	Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress – Complete B cell depletion, rapid reduction in autoantibodies and near-complete resolut Exhibit 99.1 Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress – Complete B cell depletion, rapid reduction in autoantibodies and near-complete resolution of clinical symptoms in two of three refractory patients; all three patients remained off immunomodulators since infusion and are off
October 9, 2025	8-K	FORM 8-K Item 7.01 Regulation FD Disclosure. Item 8.01 Other Events. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 09, 2025 CABALETTA BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39103 82-1685768 (State or Other Jurisdiction of Incorporation) (Commission Fi
October 9, 2025	EX-99.2	Corporate Presentation October 2025 Corporate Presentation October 2025 Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document distributed at or in connection with the presentation (collectively, the “Presentation”) has been prepared by Cabaletta Bio, Inc.
September 3, 2025	EX-99.1	Corporate Presentation September 2025 Corporate Presentation September 2025 Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document distributed at or in connection with the presentation (collectively, the “Presentation”) has been prepared by Cabaletta Bio, Inc.
September 3, 2025	8-K	FORM 8-K Item 7.01 Regulation FD Disclosure. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 03, 2025 CABALETTA BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39103 82-1685768 (State or Other Jurisdiction of Incorporation) (Commission
August 13, 2025	LETTER	LETTER August 13, 2025 Steven Nichtberger President and Chief Executive Officer Cabaletta Bio, Inc.
August 13, 2025	CORRESP	Cabaletta Bio, Inc. 2929 Arch Street, Suite 600 Philadelphia, Pennsylvania 19104 CORRESP Cabaletta Bio, Inc. 2929 Arch Street, Suite 600 Philadelphia, Pennsylvania 19104 August 13, 2025 Via EDGAR Transmission Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Joshua Gorsky Re: Cabaletta Bio, Inc.: Registration Statement on Form S-3 filed August 7, 2025 (File No. 333-289339) Ladies and Gentlemen: Pursuant to R
August 7, 2025	EX-4.4	Form of Senior Indenture between Registrant and one or more trustees to be named EX-4.4 Exhibit 4.4 CABALETTA BIO, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Senior Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s C
August 7, 2025	EX-4.5	Form of Subordinated Indenture between Registrant and one or more trustees to be named EX-4.5 Exhibit 4.5 CABALETTA BIO, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Subordinated Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s C
August 7, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39103 CABALETTA BIO, INC.
August 7, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Cabaletta Bio, Inc.
August 7, 2025	EX-99.1	Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update – Registrational cohort enrollment in RESET-Myositis™ trial on track to start in 2H25 with anticipated 2027 BLA submission for rese-cel in myositis – – Five dise Exhibit 99.1 Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update – Registrational cohort enrollment in RESET-Myositis™ trial on track to start in 2H25 with anticipated 2027 BLA submission for rese-cel in myositis – – Five disease-specific cohorts fully enrolled in the RESET™ clinical development program from over 70 clinical sites as of July 31, 2025, with expa
August 7, 2025	EX-10.1	Development and Manufacturing Services Agreement, dated as of December 19, 2024, between the Registrant and Lonza Houston Inc. Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Development and Manufacturing Services Agreement (the “Agreement”) by and between Lonza Houston Inc. 14905 Kirby
August 7, 2025	EX-1.2	Sales Agreement, dated as of August 7, 2025 between the Registrant and TD Securities (USA) LLC EX-1.2 Exhibit 1.2 CABALETTA BIO, INC. $150,000,000 COMMON STOCK SALES AGREEMENT August 7, 2025 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, NY 10017 Ladies and Gentlemen: Cabaletta Bio, Inc. (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the
August 7, 2025	S-3	As filed with the Securities and Exchange Commission on August 7, 2025 S-3 Table of Contents As filed with the Securities and Exchange Commission on August 7, 2025 Registration No.
August 7, 2025	8-K	FORM 8-K Item 2.02 Results of Operations and Financial Condition. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2025 CABALETTA BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39103 82-1685768 (State or Other Jurisdiction of Incorporation) (Commission Fil
June 12, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 CABALETTA BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39103 82-1685768 (State or Other Jurisdiction of Incorporation) (Commission File
June 12, 2025	EX-1.1	Underwriting Agreement, dated June 11, 2025, between Cabaletta Bio, Inc. and Jefferies LLC, TD Securities (USA) LLC and Cantor Fitzgerald & Co. as representatives of the several underwriters named therein. Exhibit 1.1 39,200,000 Shares of Common Stock Pre-Funded Warrants to purchase 10,800,000 Shares Warrants to Purchase 50,000,000 Shares of Common Stock (or Pre-Funded Warrants in lieu thereof) CABALETTA BIO, INC. UNDERWRITING AGREEMENT June 11, 2025 JEFFERIES LLC TD SECURITIES (USA) LLC CANTOR FITZGERALD & CO. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New Y
June 12, 2025	EX-4.1	Form of Pre-Funded Warrant. Exhibit 4.1 Form of Pre-Funded Warrant CABALETTA BIO, INC. WARRANT TO PURCHASE COMMON STOCK Number of Shares: [] (subject to adjustment) Warrant No. [] Original Issue Date: June [], 2025 Cabaletta Bio, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [] or its registered assigns (
June 12, 2025	EX-99.1	Cabaletta Bio Announces Pricing of Public Offering of Securities EX-99.1 Exhibit 99.1 Cabaletta Bio Announces Pricing of Public Offering of Securities PHILADELPHIA, June 11, 2025 — Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced today the pricing of an unde
June 12, 2025	424B5	39,200,000 Shares of Common Stock Pre-funded Warrants to Purchase up to 10,800,000 Shares of Common Stock Warrants to Purchase up to 50,000,000 Shares of Common Stock (or Pre-Funded Warrants) Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-278126 PROSPECTUS SUPPLEMENT (To prospectus dated March 31, 2025) 39,200,000 Shares of Common Stock Pre-funded Warrants to Purchase up to 10,800,000 Shares of Common Stock Warrants to Purchase up to 50,000,000 Shares of Common Stock (or Pre-Funded Warrants) We are selling 39,200,000 shares of our common stock, par value $0.000
June 12, 2025	EX-4.2	Form of Common Stock Warrant. Exhibit 4.2 CABALETTA BIO, INC. WARRANT TO PURCHASE COMMON STOCK OR PRE-FUNDED WARRANTS Number of Shares: [] (subject to adjustment) Warrant No. [] Original Issue Date: June [], 2025 Cabaletta Bio, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [] or its registered assigns (the
June 11, 2025	EX-99.2	Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document distr EX-99.2 Corporate Presentation JUNE 2025 Exhibit 99.2 Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document distributed at or in connection with the presentation (collectively, the “Presentation”) has been pre
June 11, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 June 11, 2025 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 June 11, 2025 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorporation) (Commission File N
June 11, 2025	EX-99.1	Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress – 7 of 8 myositis patients achieved clinically meaningful TIS responses after discontinuation of EX-99.1 Exhibit 99.1 Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress – 7 of 8 myositis patients achieved clinically meaningful TIS responses after discontinuation of all immunomodulators, while off or actively tapering steroids; responses were sustained throughout the follow-up period in all r
June 11, 2025	424B5	Subject to Completion Preliminary Prospectus Supplement dated June 11, 2025 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-278126 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell
June 10, 2025	EX-3.1	Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CABALETTA BIO, INC. Cabaletta Bio, Inc. (the “Corporation”), a corporation duly organized and existing under the laws of the State of Delaware pursuant to Section 242 of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows: 1. The Third Amended and
June 10, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 June 9, 2025 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 June 9, 2025 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorporation) (Commission File Nu
May 19, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 CABALETTA BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39103 82-1685768 (State or Other Jurisdiction of Incorporation) (Commission File N
May 15, 2025	8-K	FORM 8-K Item 2.02 Results of Operations and Financial Condition. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 CABALETTA BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39103 82-1685768 (State or Other Jurisdiction of Incorporation) (Commission File N
May 15, 2025	EX-99.1	Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts – Two subtype specific cohorts with ~15 patients each added to the ongoing RESET-MyositisTM trial – – RMAT designati Exhibit 99.1 Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts – Two subtype specific cohorts with ~15 patients each added to the ongoing RESET-MyositisTM trial – – RMAT designation granted for rese-cel in myositis, which is a disabling, multi-system autoimmune disease affecting approximately 80,000 U.S. patients w
May 15, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39103 CABALETTA BIO, INC.
May 13, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte
May 13, 2025	ARS	ARS &$%$/(77$ %,2 ,1& $118$/ 5(3257 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 30, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 31, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Cabaletta Bio, Inc.
March 31, 2025	EX-99.1	Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update – FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week acro Exhibit 99.1 Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update – FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET™ clinical development program since ACR Convergence presentation in November 2024 with 33 patients enrolled across 56 active
March 31, 2025	POS AM	As filed with the Securities and Exchange Commission on March 31, 2025 Table of Contents As filed with the Securities and Exchange Commission on March 31, 2025 Registration No.
March 31, 2025	EX-10.17	Fourth Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.17 CABALETTA BIO, INC. FOURTH AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Third Amended and Restated Non-Employee Director Compensation Policy of Cabaletta Bio, Inc. (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or office
March 31, 2025	EX-21.1	List of Subsidiaries of the Registrant Exhibit 21.1 Cabaletta Bio, Inc. The following is a list of subsidiaries of Cabaletta Bio, Inc. as of December 31, 2024. SUBSIDIARY STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION Cabaletta Bio, Inc. Delaware Cabaletta Bio GmbH Switzerland Cabaletta Bio (Germany) GmbH Germany
March 31, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 CABALETTA BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39103 82-1685768 (State or Other Jurisdiction of Incorporation) (Commission File
March 31, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Cabaletta Bio, Inc.
March 31, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39103 CABALETTA BIO,
March 31, 2025	EX-19.1	Insider Trading Policy Exhibit 19.1 CABALETTA BIO, INC. STATEMENT OF COMPANY POLICY ON INSIDER TRADING AND DISCLOSURE This memorandum sets forth the policy of Cabaletta Bio, Inc. and its subsidiaries (collectively, the “Company”) regarding trading in the Company’s securities as described below and the disclosure of information concerning the Company. This Insider Trading Policy (the “Insider Trading Policy”) is designed
March 31, 2025	S-8	As filed with the Securities and Exchange Commission on March 31, 2025 As filed with the Securities and Exchange Commission on March 31, 2025 Registration No.
March 31, 2025	POSASR	Power of Attorney (included on signature pages hereto) Table of Contents As filed with the Securities and Exchange Commission on March 31, 2025 Registration No.
February 18, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 February 18, 2025 Date of Report (Date of earliest event reported) CABALETTA BIO, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 February 18, 2025 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorporation) (Commission Fi
February 18, 2025	8-K/A	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 February 18, 2025 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorpora
February 18, 2025	EX-99.1	Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific – Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, th EX-99.1 Exhibit 99.1 Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings – Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining a major TIS impr
February 18, 2025	EX-99.2	Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific – Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, th EX-99.2 Exhibit 99.2 Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings – Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining a major TIS impr
February 18, 2025	EX-99.1	Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any docum EX-99.1 Corporate Presentation FEBRUary 2025 Exhibit 99.1 Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (collectively, the “Pr
February 5, 2025	EX-24	EX-24 EX-24 2 PowerOfAttorney.txt EXHIBIT 24: POWER OF ATTORNEY POWER OF ATTORNEY The undersigned, BlackRock, Inc., a corporation duly organized under the laws of the State of Delaware, United States (the "Company"), does hereby make, constitute and appoint each of Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Laura Hildner, David Maryles, Christopher Meade, Charles Park, Jam
February 5, 2025	EX-99	EX-99 EX-99 3 ITEM7.txt EXHIBIT 99: ITEM 7 BlackRock Advisors, LLC BlackRock Asset Management Canada Limited BlackRock Fund Advisors BlackRock Institutional Trust Company, National Association BlackRock Financial Management, Inc. BlackRock Japan Co., Ltd. BlackRock Investment Management, LLC *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Sc
January 13, 2025	EX-99.1	Corporate Presentation JANUARY 2025 © 2025 Cabaletta Bio. All rights reserved. Exhibit 99.1 Corporate Presentation JANUARY 2025 © 2025 Cabaletta Bio. All rights reserved. Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the
January 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 January 13, 2025 Date of Report (Date of earliest event reported) CABALETTA BIO, IN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 January 13, 2025 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorporation) (Commission Fil
January 13, 2025	EX-99.2	Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025 – Company plans to meet with the FDA to align on registrational trial designs in 1H25 based on emerging clinical profile of resecabtagene autoleucel (rese-cel, former Exhibit 99.2 Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025 – Company plans to meet with the FDA to align on registrational trial designs in 1H25 based on emerging clinical profile of resecabtagene autoleucel (rese-cel, formerly referred to as CABA-201) and increased pace of enrollment with 44 active clinical trial sites – – Favorable safety profile observed ac
December 6, 2024	SC 13G/A	CABA / Cabaletta Bio, Inc. / ALGER ASSOCIATES INC - CABALETTA BIO, INC. Passive Investment Cabaletta Bio, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Cabaletta Bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 12674W109 (CUSIP Number) November 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua
December 5, 2024	SC 13G/A	CABA / Cabaletta Bio, Inc. / PRUDENTIAL FINANCIAL INC Passive Investment SC 13G/A 1 caba2.htm DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment # 1 Name of Issuer: CABALETTA BIO INC Title of Class of Securities: Common Stock CUSIP Number: 12674W109 1) NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSON Prudential Financial, Inc. 22-3703799 2.) MEMBER OF A GROUP: (a)
December 5, 2024	SC 13G/A	CABA / Cabaletta Bio, Inc. / JENNISON ASSOCIATES LLC - CABA 11302024 13G/A Passive Investment SC 13G/A 1 CABA1124.txt CABA 11302024 13G/A Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* November 30, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this schedule is filed: (X) Rule 13d-1(b) ( ) Rule 13d-1(c) ( ) Rule 13d-1(d) Name o
November 18, 2024	EX-99.2	Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 – CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight patients EX-99.2 Exhibit 99.2 Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 – CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight patients and one previously reported ICANS event – – Compelling clinical responses observed in lupus and myositis patients with up to s
November 18, 2024	EX-99.4	Disclosures Author Disclosures David J. Chang Employee: Cabaletta Bio Saira Sheikh Consultant: AstraZeneca; Biogen; Cabaletta Bio; GSK Tahseen Mozaffar Advisor or Review Panel Member, Grant/Research Support: Amicus; AnnJi; Argenx; Astellas Gene Thera EX-99.4 Safety and efficacy of CABA-201, a fully human, autologous 4-1BB anti-CD19 CAR T cell therapy in patients with immune-mediated necrotizing myopathy and systemic lupus erythematosus from the RESET-Myositis™ and RESET-SLE™ clinical trials Saira Sheikh1; Tahseen Mozaffar2; Vimal Derebail1; Natalie Grover1; Jonathan Hogan3; Courtney Little3; Yvonne White3; Claire Miller3; Rebecca Estremera3; J
November 18, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 November 18, 2024 Date of Report (Date of earliest event reported) CABALETTA BIO, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 November 18, 2024 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorporation) (Commission Fi
November 18, 2024	EX-99.1	Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any docum EX-99.1 Exhibit 99.1 CABA-201 Clinical and Translational Data from the RESET Phase 1/2 Trials NOVEMBER 2024 © 2024 Cabaletta Bio. All rights reserved. Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any docu
November 18, 2024	EX-99.3	Poster presentation from Cabaletta Bio, Inc., dated November 16, 2024 Exhibit 99.3 Correlative Studies of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in #0324 Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the Presented at the TM TM ACR Convergence 2024 RESET-Myositis and RESET-SLE Clinical Trials 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 Nov 14-19, 2024 Daniel Nunez , Jenell Volkov , Jason Stadanlick , Za
November 14, 2024	EX-10.3	Amendment to the Services Agreement, dated as of September 30, 2024, between the Registrant and CIC Innovation Communities, LLC Exhibit 10.3 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SERVICE AGREEMENT Amendment AMENDMENT TO SERVICE AGREEMENT CIC and Client hereby agree to supplement the Service
November 14, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 CABALETTA BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39103 82-1685768 (State or Other Jurisdiction of Incorporation) (Commission F
November 14, 2024	SC 13G/A	CABA / Cabaletta Bio, Inc. / Venrock Healthcare Capital Partners III, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm2428137d4sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Cabaletta Bio, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 12674W109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement)
November 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39103 CABALETTA BIO, INC.
November 14, 2024	EX-10.1	Services Agreement, dated as of February 1, 2019, between the Registrant and CIC Innovation Communities, LLC Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SERVICE AGREEMENT The licensee(s) identified on the signature block of this agreement (the “Licensee”) and CIC he
November 14, 2024	EX-10.2	Amendment to the Services Agreement, dated as of December 1, 2021, between the Registrant and CIC Innovation Communities, LLC Exhibit 10.2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Large Lab Client Customization Agreement 12/1/21 Terms for new space and fees for Cabaletta Bio custom laboratory
November 14, 2024	EX-10.4	Second Amendment, dated September 24, 2024, to the Lease, dated as of February 11, 2019, between the Registrant and Brandywine Cira, L.P., as amended. Exhibit 10.4 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE (“Amendment”) is made and entered into as of October 1,
November 14, 2024	SC 13G	CABA / Cabaletta Bio, Inc. / T. Rowe Price Investment Management, Inc. Passive Investment SC 13G 1 caba13gsep24.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) CABALETTA BIO INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 12674W109 (CUSIP NUMBER) September 30, 2024 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant
November 14, 2024	SC 13G/A	CABA / Cabaletta Bio, Inc. / ALGER ASSOCIATES INC - CABALETTA BIO, INC. Passive Investment SC 13G/A 1 d891197dsc13ga.htm CABALETTA BIO, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Cabaletta Bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 12674W109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate b
November 14, 2024	EX-99.1	Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update – Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this weekend in oral a Exhibit 99.1 Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update – Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this weekend in oral and poster presentations at ACR Convergence 2024 – – 16 patients enrolled with 10 patients dosed as of November 12 across the RESET™ clini
November 12, 2024	SC 13G/A	CABA / Cabaletta Bio, Inc. / Adage Capital Management, L.P. - CABALETTA BIO, INC. Passive Investment SC 13G/A 1 p24-3076sc13ga.htm CABALETTA BIO, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5), * Cabaletta Bio, Inc. (Name of Issuer) Voting Common Stock, par value $0.00001 per share (Title of Class of Securities) 12674W109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This State
November 12, 2024	SC 13G/A	CABA / Cabaletta Bio, Inc. / VANGUARD GROUP INC Passive Investment 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Cabaletta Bio Inc (Title of Class of Securities) Common Stock (CUSIP Number) 12674W10
November 4, 2024	SC 13G/A	CABA / Cabaletta Bio, Inc. / VANGUARD GROUP INC Passive Investment SC 13G/A 1 UnitedStates13GCabalettaB.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* (Name of Issuer) Cabaletta Bio Inc (Title of Class of Securiti
November 4, 2024	SC 13G/A	CABA / Cabaletta Bio, Inc. / VANGUARD GROUP INC Passive Investment 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* (Name of Issuer) Cabaletta Bio Inc (Title of Class of Securities) Common Stock (CUSIP Number) 12674W109
November 4, 2024	SC 13G/A	CABA / Cabaletta Bio, Inc. / VANGUARD GROUP INC Passive Investment SC 13G/A 1 UnitedStates13GCabalettaB.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* (Name of Issuer) Cabaletta Bio Inc (Title of Class of Securiti
October 17, 2024	SC 13G/A	CABA / Cabaletta Bio, Inc. / STATE STREET CORP Passive Investment SC 13G/A 1 CabalettaBioInc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CABALETTA BIO INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 12674W109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to
October 7, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 October 7, 2024 Date of Report (Date of earliest event reported) CABALETTA BIO, INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 October 7, 2024 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorporation) (Commission File
October 7, 2024	EX-99.1	Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any docum EX-99.1 Corporate Presentation OCTOBER 2024 Exhibit 99.1 Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (collectively, the “Pre
September 30, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 CABALETTA BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39103 82-1685768 (State or Other Jurisdiction of Incorporation) (Commission
August 22, 2024	SC 13G	CABA / Cabaletta Bio, Inc. / Bain Capital Life Sciences Opportunities III, LP - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.
August 8, 2024	EX-10.1	Fourth Amendment to the Licence and Supply Agreement, dated as of June 24, 2024, between the Registrant and Oxford Biomedica (UK) Limited Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Fourth Amendment Agreement This fourth amendment agreement (“Agreement”) is dated the date of the last signature
August 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 August 8, 2024 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 August 8, 2024 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorporation) (Commission File
August 8, 2024	EX-99.1	Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update – Nine patients enrolled as of August 5, 2024 across the RESET™ clinical development program, including four since EULAR in June, with 22 U.S. clinical sites now Exhibit 99.1 Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update – Nine patients enrolled as of August 5, 2024 across the RESET™ clinical development program, including four since EULAR in June, with 22 U.S. clinical sites now enrolling – – Additional clinical data from the RESET-Myositis™ and RESET-SLE™ trials as well as initial clinical data from the RESET-SS
August 8, 2024	EX-99.2	Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any docum EX-99.2 Corporate Presentation augusT 2024 Exhibit 99.2 Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (collectively, the “Pres
August 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39103 CABALETTA BIO, INC.
June 14, 2024	EX-99.3	Symposium Speakers Drs Georg Schett and Carl June are members of Cabaletta Bio’s Scientific Advisory Board. David J. Chang, MD, MPH, FACR Chief Medical Oﬃcer Cabaletta Bio Philadelphia, PA Carl H. June, MD Director of the Center for Cellular Immunoth IMMUNE Reset: The potential of car t cell therapy to transform the treatment of patients with autoimmune disease Exhibit 99.
June 14, 2024	EX-99.1	Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any docum CABA-201 Initial Clinical Data from the RESET-Myositis™ & RESET-SLE™ Phase 1/2 Trials JUNE 2024 Exhibit 99.
June 14, 2024	EX-99.2	Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201 – No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2 Exhibit 99.2 Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201 – No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 – – CABA-201 exhibited anticipated profile of CAR T cell expansion and contraction with complete B cell depletion observed in both pa
June 14, 2024	8-K	Regulation FD Disclosure, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 June 14, 2024 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorporation) (Commission File N
June 10, 2024	SC 13G	CABA / Cabaletta Bio, Inc. / PRUDENTIAL FINANCIAL INC Passive Investment 13G HTML File DOCUMENT TYPE SC 13G TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 6, 2024	SC 13G	CABA / Cabaletta Bio, Inc. / JENNISON ASSOCIATES LLC - 13G MONTHLY FILING - CABA Passive Investment SC 13G 1 CABA0524.txt 13G MONTHLY FILING - CABA Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 0)* May 31, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this schedule is filed: (X) Rule 13d-1(b) ( ) Rule 13d-1(c) ( ) Rule 13d-1(d) Name of
June 4, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 June 3, 2024 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorporation) (Commission File Nu
May 15, 2024	EX-99.2	Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any docum EX-99.2 Exhibit 99.2 Corporate Presentation MAY 2024 © 2024 Cabaletta Bio. All rights reserved. Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with t
May 15, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 May 15, 2024 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 May 15, 2024 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorporation) (Commission File Nu
May 15, 2024	EX-10.1	Third Amendment to the Licence and Supply Agreement, dated as of February 21, 2024, between the Registrant and Oxford Biomedica (UK) Limited Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Amendment Agreement This amendment agreement (“Agreement”) is dated 21st February 2024 PARTIES (1) OXFORD BIOMEDI
May 15, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39103 CABALETTA BIO, INC.
May 15, 2024	EX-99.1	Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update – No CRS or ICANS of any grade observed during the 28-day DLT observation window for either of the first patients dosed with CABA-201 in the RESET-Myositis™ and R EX-99.1 Exhibit 99.1 Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update – No CRS or ICANS of any grade observed during the 28-day DLT observation window for either of the first patients dosed with CABA-201 in the RESET-Myositis™ and RESET-SLE™ trials – – Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials to be prese
April 23, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 23, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte
April 23, 2024	ARS	ARS CABALETTABIO,INC. 2023ANNUALREPORTUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission Fil
March 21, 2024	EX-4.4	Form of Subordinated Indenture between Registrant and one or more trustees to be named Exhibit 4.4 CABALETTA BIO, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Subordinated Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.0 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certifica
March 21, 2024	EX-99.7	Cabaletta Bio, Inc.'s Compensation Recovery Policy Exhibit 99.7 CABALETTA BIO, INC. COMPENSATION RECOVERY POLICY Cabaletta Bio, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as defined below) in accordance with r
March 21, 2024	EX-99.1	Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update – First patient dosed with CABA-201 in the RESET™ (REstoring SElf-Tolerance) clinical trial program – – Initial clinical data from each of the firs Exhibit 99.1 Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update – First patient dosed with CABA-201 in the RESET™ (REstoring SElf-Tolerance) clinical trial program – – Initial clinical data from each of the first patients in the RESET-Myositis™ and RESET-SLE™ trials anticipated in 1H24; longer term follow-up on these and additional patients to be
March 21, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39103 CABALETTA BIO,
March 21, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Cabaletta Bio, Inc.
March 21, 2024	EX-21.1	List of Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries None.
March 21, 2024	S-8	As filed with the Securities and Exchange Commission on March 21, 2024 As filed with the Securities and Exchange Commission on March 21, 2024 Registration No.
March 21, 2024	EX-1.2	Sales Agreement, dated as of March 21, 2024 between the Registrant and Cowen and Company, LLC Exhibit 1.2 CABALETTA BIO, INC. $200,000,000 COMMON STOCK SALES AGREEMENT March 21, 2024 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Cabaletta Bio, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the term of th
March 21, 2024	EX-10.19	Third Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.19 CABALETTA BIO, INC. THIRD AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Third Amended and Restated Non-Employee Director Compensation Policy of Cabaletta Bio, Inc. (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officer
March 21, 2024	S-3ASR	As filed with the Securities and Exchange Commission on March 21, 2024 Table of Contents As filed with the Securities and Exchange Commission on March 21, 2024 Registration No.
March 21, 2024	EX-4.3	Form of Senior Indenture between Registrant and one or more trustees to be named (incorporated by reference to Exhibit 4.3 to the Registrant’s Registration Statement on Form S-3 (File No. 333-278126) field with the SEC on March 21, 2024) Exhibit 4.3 CABALETTA BIO, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Senior Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate 6
March 21, 2024	EX-4.3	Description of Securities (incorporated by reference to Exhibit 4.3 of the Registrant’s Annual Report on Form 10-K (File No. 001-39103) filed with the Securities and Exchange Commission on March 21, 2024). Exhibit 4.3 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended The following summary of the general terms and provisions of the registered capital stock of Cabaletta Bio, Inc. (“Cabaletta”, “we”, “our”) does not purport to be complete and is subject to, and qualified in its entirety by, reference to our Third Amended and
March 21, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3ASR (Form Type) Cabaletta Bio, Inc.
March 21, 2024	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 March 21, 2024 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorporation) (Commission File
March 20, 2024	EX-99.1	Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis Exhibit 99.1 Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis PHILADELPHIA, March 20, 2024 — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the U.S. Food and Drug Administrat
March 20, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2024 CABALETTA BIO, INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2024 CABALETTA BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorporation) (Commission File
February 14, 2024	SC 13G/A	CABA / Cabaletta Bio, Inc. / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SC 13G/A 1 tm242424d12sc13ga.htm SC 13G/A SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Cabaletta Bio, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 12674W109 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropri
February 14, 2024	SC 13G/A	CABA / Cabaletta Bio, Inc. / Lynx1 Capital Management LP - CABALETTA BIO, INC. Passive Investment SC 13G/A 1 p24-0765sc13ga.htm CABALETTA BIO, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Cabaletta Bio, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 12674W109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check
February 14, 2024	SC 13G/A	CABA / Cabaletta Bio, Inc. / COMMODORE CAPITAL LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 14, 2024	SC 13G/A	CABA / Cabaletta Bio, Inc. / Venrock Healthcare Capital Partners III, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm246235d4sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Cabaletta Bio, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 12674W109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) C
February 14, 2024	SC 13G/A	CABA / Cabaletta Bio, Inc. / ALGER ASSOCIATES INC - CABALETTA BIO, INC. Passive Investment SC 13G/A 1 d743764dsc13ga.htm CABALETTA BIO, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Cabaletta Bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 12674W109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo
February 14, 2024	SC 13G/A	CABA / Cabaletta Bio, Inc. / Cormorant Asset Management, LP - AMENDMENT NO. 2 Passive Investment SC 13G/A 1 sc13ga.htm AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Cabaletta Bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 12674W109 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designa
February 13, 2024	SC 13G/A	CABA / Cabaletta Bio, Inc. / Bain Capital Life Sciences Opportunities III, LP - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.
February 13, 2024	SC 13G/A	CABA / Cabaletta Bio, Inc. / Nichtberger Steven - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Cabaletta Bio, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 12674W109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design
February 12, 2024	SC 13G/A	CABA / Cabaletta Bio, Inc. / Flynn James E Passive Investment SC 13G/A 1 e619242sc13ga-cb.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1) * Cabaletta Bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 12674W109 (CUSIP Number) December 31, 2023
February 7, 2024	SC 13G/A	CABA / Cabaletta Bio, Inc. / ADAGE CAPITAL PARTNERS GP, L.L.C. - CABALETTA BIO, INC. Passive Investment SC 13G/A 1 p24-0432sc13ga.htm CABALETTA BIO, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Cabaletta Bio, Inc. (Name of Issuer) Voting Common Stock, $0.00001 par value per share (Title of Class of Securities) 12674W109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement)
February 1, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2024 CABALETTA BIO, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2024 CABALETTA BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorporation) (Commission Fi
February 1, 2024	EX-99.1	Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis Exhibit 99.1 Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis PHILADELPHIA, Feb. 1, 2024 — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) ha
January 24, 2024	SC 13G	CABA / Cabaletta Bio, Inc. / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 INITIAL FILING CABALETTA BIO INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 12674W109 (CUSIP NUMBER) 12/31/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILE
January 8, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 CABALETTA BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorporation) (Commission Fil
January 8, 2024	SC 13G	CABA / Cabaletta Bio, Inc. / BlackRock Inc. Passive Investment SC 13G 1 us12674w1099010824.txt us12674w1099010824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) Cabaletta Bio, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 12674W109 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box t
January 8, 2024	EX-99.1	Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any docum Exhibit 99.1 Corporate Presentation JANUARY 2024 © 2024 Cabaletta Bio. All rights reserved. Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the p
January 8, 2024	EX-99.2	Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis – Second and third FDA Fast Track Designations for CABA-201, following the systemic lupus erythematosus (SLE) and lupus nephritis (LN Exhibit 99.2 Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis – Second and third FDA Fast Track Designations for CABA-201, following the systemic lupus erythematosus (SLE) and lupus nephritis (LN) designation, providing the opportunity for expedited development and review of CABA-201 for the treatment of these autoimmune diseases
November 9, 2023	EX-99.2	Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any docum Corporate Presentation NOVEMBER 2023 Exhibit 99.2 Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (collectively, the “Presentati
November 9, 2023	EX-10.1	Second Amendment to the Licence and Supply Agreement, dated as of August 18, 2023, between the Registrant and Oxford Biomedica (UK) Limited (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-39103) filed on November 9, 2023) Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Cabaletta Bio, Inc. 2929 Arch Street, Suite 600, Philadelphia, PA 19104, USA Attention: CEO 16 Aug 2023 To whom i
November 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39103 CABALETTA BIO, INC.
November 9, 2023	EX-10.2	Amendment No. 5, dated July 25, 2023, to the Sponsored Research Agreement, dated April 23, 2018, between the Registrant and the Trustees of the University of Pennsylvania Exhibit 10.2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 5 TO SPONSORED RESEARCH AGREEMENT This Amendment No. 5 to the Sponsored Research Agreement (“Amendm
November 9, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 November 9, 2023 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorporation) (Commission Fil
November 9, 2023	EX-99.1	Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update – Initial clinical data from CABA-201 treated patients in Phase 1/2 trials for lupus and/or myositis expected in the first half of 2024, with the first lupus clin Exhibit 99.1 Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update – Initial clinical data from CABA-201 treated patients in Phase 1/2 trials for lupus and/or myositis expected in the first half of 2024, with the first lupus clinical site actively recruiting patients – – Expanded CABA-201 clinical development program within rheumatology and into neurology with add
November 6, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 November 6, 2023 Date of Report (Date of earliest event reported) CABALETTA BIO, IN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 November 6, 2023 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorporation) (Commission Fil
November 6, 2023	EX-99.1	Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis – First cleared CD19-CAR T IND application for generalized myasthenia gravis announced in the U.S. and fourth IND clearance for CABA-201 a Exhibit 99.1 Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis – First cleared CD19-CAR T IND application for generalized myasthenia gravis announced in the U.S. and fourth IND clearance for CABA-201 across a broad range of autoimmune diseases – – Clearance expands the clinical development of CABA-201 beyond rheumatology into neurology
October 2, 2023	8-K	Regulation FD Disclosure, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 October 2, 2023 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorporation) (Commission File
October 2, 2023	EX-99.2	Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201 – Third IND application clearance for CABA-201 within the past 6 months across a broad range of autoimmune diseases – – Phase 1/2 clinical trial Exhibit 99.2 Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201 – Third IND application clearance for CABA-201 within the past 6 months across a broad range of autoimmune diseases – – Phase 1/2 clinical trial evaluating CABA-201 in systemic sclerosis features parallel cohort design and the same starting dose as the CABA-201 INDs for lupus and
October 2, 2023	EX-99.1	Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any docum Exhibit 99.1 Corporate Presentation OCTOBER 2023 © 2023 Cabaletta Bio. All rights reserved. Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the p
September 5, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 September 5, 2023 Date of Report (Date of earliest event reported) CABALETTA BIO, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 September 5, 2023 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorporation) (Commission Fi
September 5, 2023	EX-99.1	Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any docum EX-99.1 Corporate Presentation September 2023 Exhibit 99.1 Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (collectively, the “P
August 22, 2023	EX-99.1	Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201 – Agreement expansion facilitates preparation for commercial readiness for CABA-201, enabling treatment of patients in multiple planned cl Exhibit 99.1 Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201 – Agreement expansion facilitates preparation for commercial readiness for CABA-201, enabling treatment of patients in multiple planned clinical trials with separate parallel cohorts – – Partnership for CABA-201 builds on existing manufacturing agreement for clinical trial s
August 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 August 18, 2023 Date of Report (Date of earliest event reported) CABALETTA BIO, INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 August 18, 2023 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorporation) (Commission File
August 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 August 10, 2023 Date of Report (Date of earliest event reported) CABALETTA BIO, INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 August 10, 2023 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorporation) (Commission File
August 10, 2023	EX-10.3	Second Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.3 CABALETTA BIO, INC. SECOND AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Amended and Restated Non-Employee Director Compensation Policy of Cabaletta Bio, Inc. (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of t
August 10, 2023	S-8	As filed with the Securities and Exchange Commission on August 10, 2023 S-8 As filed with the Securities and Exchange Commission on August 10, 2023 Registration No.
August 10, 2023	EX-99.1	Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update – Received second IND application clearance for CABA-201 in myositis as well as Fast Track Designation in SLE and LN – – Strengthened balance sheet by closing $1 EX-99.1 Exhibit 99.1 Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update – Received second IND application clearance for CABA-201 in myositis as well as Fast Track Designation in SLE and LN – – Strengthened balance sheet by closing $100M public offering extending cash runway into the fourth quarter of 2025 – PHILADELPHIA, Aug. 10, 2023 – Cabaletta Bio, Inc. (Na
August 10, 2023	EX-10.2	First Amendment to the Licence and Supply Agreement, dated as of May 2, 2023, between the Registrant and Oxford Biomedica (UK) Limited (incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-39103) filed on August 10, 2023) Exhibit 10.2 Cabaletta Bio, Inc. 2929 Arch Street, Suite 600, Philadelphia, PA 19104, USA Attention: CEO 27 March 2023 To whom it may concern Amendment to Licence and Supply Agreement 1. We refer to the Licence and Supply Agreement dated 30 December 2021 entered into between Oxford Biomedica (UK) Limited and Cabaletta Bio, Inc. (the “Licence Agreement”). Unless expressly defined herein, capitalise
August 10, 2023	EX-FILING FEES	Filing Fee Table. EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Cabaletta Bio, Inc.
August 10, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39103 CABALETTA BIO, INC.
July 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2023 CABALETTA BIO, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2023 CABALETTA BIO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorporation) (Commission File
July 24, 2023	EX-99.2	Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any docum Corporate Presentation JULY 2023 Exhibit 99.2 Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (collectively, the “Presentation”)
July 24, 2023	EX-99.1	Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors – Ms. Tomasello created and led global commercial and medical affairs functions at Kite Pharma from pre-launch through its acquisition by Gilead Sciences – EX-99.1 Exhibit 99.1 Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors – Ms. Tomasello created and led global commercial and medical affairs functions at Kite Pharma from pre-launch through its acquisition by Gilead Sciences – PHILADELPHIA, July 24, 2023 – Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launch
June 1, 2023	SC 13G	CABA / Cabaletta Bio Inc / Bain Capital Life Sciences Opportunities III, LP - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.
June 1, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 June 1, 2023 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorporation) (Commission File Nu
June 1, 2023	EX-10.1	Amendment No. 1 to the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on June 1, 2023) EX-10.1 Exhibit 10.1 AMENDMENT NO. 1 TO THE CABALETTA BIO, INC. 2019 STOCK OPTION AND INCENTIVE PLAN WHEREAS, Cabaletta Bio, Inc. (the “Company”) maintains the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan (the “Plan”), which was previously adopted by the Board of Directors of the Company (the “Board”) and approved by the stockholders of the Company; WHEREAS, the Board desires to amend
May 26, 2023	SC 13G	CABA / Cabaletta Bio Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
May 22, 2023	EX-99.1	Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares EX-99.1 Exhibit 99.1 Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares PHILADELPHIA, May 22, 2023 — Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with au
May 22, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 May 22, 2023 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorporation) (Commission File Nu
May 18, 2023	EX-99.1	Cabaletta Bio Announces Pricing of Public Offering of Common Stock EX-99.1 Exhibit 99.1 Cabaletta Bio Announces Pricing of Public Offering of Common Stock PHILADELPHIA, May 17, 2023 — Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced the pricing of an underwritten public offer
May 18, 2023	424B5	7,250,000 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-270599 PROSPECTUS SUPPLEMENT (To prospectus dated April 26, 2023) 7,250,000 Shares of Common Stock We are selling 7,250,000 shares of our common stock, par value $0.00001 per share, or the common stock, in this offering pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is listed on
May 18, 2023	EX-1.1	Underwriting Agreement, dated May 17, 2023, between the Company, Cowen and Company, LLC, Evercore Group L.L.C. and Guggenheim Securities, LLC as representatives of the several underwriters named therein. Exhibit 1.1 CABALETTA BIO, INC. 7,250,000 Shares of Common Stock UNDERWRITING AGREEMENT May 17, 2023 COWEN AND COMPANY, LLC EVERCORE GROUP L.L.C. GUGGENHEIM SECURITIES, LLC As Representatives of the several Underwriters c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o Evercore Group L.L.C. 55 East 52nd Street New York, New York 10055 c/o Guggenheim Securities, LLC 330 M
May 18, 2023	424B5	Subject to Completion Preliminary Prospectus Supplement dated , 2023 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-270599 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell
May 18, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 May 17, 2023 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorporation) (Commission File Nu
May 16, 2023	EX-99.1	Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any docum EX-99.1 Corporate Presentation MAY 2023 Exhibit 99.1 Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (collectively, the “Present
May 16, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 May 16, 2023 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorporation) (Commission File Nu
May 16, 2023	EX-99.1	Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis EX-99.1 Exhibit 99.1 Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis — Phase 1/2 trial for CABA-201 planned to initiate in patients with myositis at an initial dose that is equivalent to the dose used in a patient with myositis as reported in the recent Lancet Rheumatology publication – — Second IND clearance for CABA-201, obtained within two months o
May 16, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 May 16, 2023 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 May 16, 2023 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorporation) (Commission File Nu
May 11, 2023	EX-99.1	Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update – IND application cleared within 30 days for clinical trial of CABA-201 in patients with LN and SLE and Fast Track Designation granted by the FDA for CABA-201 to EX-99.1 Exhibit 99.1 Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update – IND application cleared within 30 days for clinical trial of CABA-201 in patients with LN and SLE and Fast Track Designation granted by the FDA for CABA-201 to deplete CD19-positive B cells and improve disease activity in patients with LN and SLE – – Phase 1/2 trial planned to evaluate CA
May 11, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39103 CABALETTA BIO, INC.
May 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 May 11, 2023 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 May 11, 2023 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorporation) (Commission File Nu
May 11, 2023	EX-10	Master Translational Research Services Agreement, dated as of February 9, 2023, between the Registrant and the Trustees of the University of Pennsylvania Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. MASTER TRANSLATIONAL RESEARCH SERVICES AGREEMENT This Master Translational Research Services Agreement (“Agreemen
May 2, 2023	EX-99.1	Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting EX-99.1 Exhibit 99.1 Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting PHILADELPHIA, May 2, 2023 — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Samik Basu, M.D., Chief Scientific Officer
May 2, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 May 2, 2023 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 May 2, 2023 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorporation) (Commission File Num
May 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 May 1, 2023 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 May 1, 2023 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorporation) (Commission File Num
May 1, 2023	EX-99.1	Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any docum EX-99.1 Corporate Presentation MAY 2023 Exhibit 99.1 Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (collectively, the “Present
May 1, 2023	EX-99.2	Cabaletta Bio Receives FDA Fast Track Designation for CABA-201 EX-99.2 Exhibit 99.2 Cabaletta Bio Receives FDA Fast Track Designation for CABA-201 PHILADELPHIA, May 1, 2023 — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designa
April 24, 2023	CORRESP	Cabaletta Bio, Inc. 2929 Arch Street, Suite 600 Philadelphia, Pennsylvania 19104 Cabaletta Bio, Inc. 2929 Arch Street, Suite 600 Philadelphia, Pennsylvania 19104 April 24, 2023 Via EDGAR Transmission Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan R. Campbell Re: Cabaletta Bio, Inc.: Registration Statement on Form S-3 filed March 16, 2023 (File No. 333-270599) Ladies and Gentlemen: Pursuant to Rule 46
April 21, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 21, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule
April 21, 2023	ARS	ARS CABALETTABIO,INC. 2022ANNUALREPORT UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM10-K (MarkOne) " ANNUALREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934 ForthefiscalyearendedDecember31,2022 OR ! TRANSITIONREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF 1934FORTHETRANSITIONPERIODFROM TO CommissionFileNumber001-39103 CABALETTABIO,INC. (Exactnameof
March 31, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 March 31, 2023 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 March 31, 2023 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorporation) (Commission File
March 31, 2023	EX-99.1	Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any docum EX-99.1 2 d491365dex991.htm EX-99.1 Corporate Presentation March 2023 Exhibit 99.1 Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentati
March 31, 2023	EX-99.2	- IND application cleared within 6 months of in-licensing CABA-201 binder - CABA-201 data package and experience from prior autoimmune cell therapy INDs informed Phase 1/2 clinical trial design, including the initial dose to be evaluated and the pati EX-99.2 Exhibit 99.2 Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Systemic Lupus Erythematosus - IND application cleared within 6 months of in-licensing CABA-201 binder - CABA-201 data package and experience from prior autoimmune cell therapy INDs informed Phase 1/2 clinical trial design, including the initial dose to be evaluated and the patient dosing int
March 22, 2023	LETTER	LETTER United States securities and exchange commission logo March 22, 2023 Steven Nichtberger President and Chief Executive Officer Cabaletta Bio, Inc.
March 16, 2023	S-8	Power of Attorney (included on signature page). S-8 As filed with the Securities and Exchange Commission on March 16, 2023 Registration No.
March 16, 2023	EX-99.1	Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update – Company expecting Investigational New Drug (IND) clearance in the first half of 2023 for CABA-201, a 4-1BB-containing fully human CD19-CAR T cell Exhibit 99.1 Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update – Company expecting Investigational New Drug (IND) clearance in the first half of 2023 for CABA-201, a 4-1BB-containing fully human CD19-CAR T cell therapy, with potential to generate initial clinical data by the first half of 2024 – PHILADELPHIA, March 16, 2023 – Cabaletta Bio, Inc.
March 16, 2023	EX-4.3	Form of Senior Indenture between Registrant and one or more trustees to be named EX-4.3 Exhibit 4.3 CABALETTA BIO, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Senior Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certifi
March 16, 2023	EX-1.2	Sales Agreement, dated as of March 16, 2023 between the Registrant and Cowen and Company, LLC Exhibit 1.2 CABALETTA BIO, INC. $100,000,000 COMMON STOCK SALES AGREEMENT March 16, 2023 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Cabaletta Bio, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the term of th
March 16, 2023	10-K	Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39103 CABALETTA BIO,
March 16, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Cabaletta Bio, Inc.
March 16, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 March 16, 2023 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 March 16, 2023 Date of Report (Date of earliest event reported) CABALETTA BIO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-39103 82-1685768 (State or other jurisdiction of incorporation) (Commission File
March 16, 2023	EX-21	List of Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries None.
March 16, 2023	EX-99.2	Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any docum EX-99.2 Corporate Presentation march 2023 Exhibit 99.2 Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (collectively, the “Prese
March 16, 2023	EX-10	Amendment No. 4, dated December 1, 2022, to the Sponsored Research Agreement, dated April 23, 2018, between the Registrant and the Trustees of the University of Pennsylvania Exhibit 10.33 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 4 TO SPONSORED RESEARCH AGREEMENT This Amendment No. 4 to the Sponsored Research Agreement (“Amend
March 16, 2023	S-3	Power of Attorney (included on signature pages hereto) S-3 Table of Contents As filed with the Securities and Exchange Commission on March 16, 2023 Registration No.
March 16, 2023	EX-4.4	Form of Subordinated Indenture between Registrant and one or more trustees to be named Exhibit 4.4 CABALETTA BIO, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Subordinated Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certific
March 16, 2023	EX-10	Development, Manufacturing, and Testing Services Agreement, dated January 11, 2021, between the Registrant and WuXi Advanced Therapies Inc. EX-10 4 caba-ex1034.htm EX-10.34 Exhibit 10.34 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. DEVELOPMENT, MANUFACTURING, AND TESTING SERVICES AGREEMENT This Development, Ma
March 16, 2023	EX-4	Description of Securities Exhibit 4.3 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended The following summary of the general terms and provisions of the registered capital stock of Cabaletta Bio, Inc. (“Cabaletta”, “we”, “our”) does not purport to be complete and is subject to, and qualified in its entirety by, reference to our Third Amended and
March 16, 2023	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Cabaletta Bio, Inc.

CABA / Cabaletta Bio, Inc. - Arquivamentos da SEC, Relatório Anual, Declaração de Procuração

Estatísticas Básicas

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?

Other Listings